Group 1 - Company Pigeon BioPharma has voluntarily applied for the dissolution of its non-wholly-owned subsidiary, Shanghai Maiji BioPharmaceutical Technology Co., Ltd, which was established on June 26, 2017, focusing on the research and development of GLP-2 [1] - The move reflects a strategic contraction by Pigeon BioPharma, indicating a focus on core pipelines and optimization of resource allocation [1] Group 2 - Hengrui Medicine's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd has had its HRS-5965 capsule proposed for inclusion in the priority review list by the National Medical Products Administration, aimed at treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitors [2] - This recognition highlights Hengrui Medicine's innovative capabilities, and if approved, the drug will address a significant treatment gap for first-line patients [2] Group 3 - Renfu Pharmaceutical's subsidiary Yichang Renfu Pharmaceutical Co., Ltd has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its pregabalin sustained-release tablets, which are intended for treating diabetic peripheral neuropathy-related neuropathic pain and postherpetic neuralgia [3] - The approval is expected to expand the market for neuropathic pain treatment, with a broad market potential for the two indications targeted by the drug [3] - The sustained-release formulation may enhance patient compliance, and successful development will enrich the company's pain management product line, although ongoing clinical progress and competition from original research drugs should be monitored [3]

Core Viewpoint - The announcement indicates that the company’s subsidiary has received approval for a clinical trial of a new drug, which could enhance its product pipeline and market position in the pharmaceutical industry [1] Group 1 - The company, Renfu Pharmaceutical, announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for the drug Pregabalin sustained-release tablets [1]

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets through its subsidiary Yichang Renfu Pharmaceutical [1] - For the year 2024, Renfu Pharmaceutical's revenue composition is as follows: 56.01% from pharmaceuticals, 43.8% from pharmaceutical wholesale and related businesses, and 0.19% from other businesses [1] - As of the report, Renfu Pharmaceutical has a market capitalization of 33.8 billion yuan [1]

Core Viewpoint - Yifan Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, which are primarily used to treat diabetic peripheral neuropathy (DPN) related neuropathic pain and postherpetic neuralgia (PHN) [1] Company Summary - Yifan Pharmaceutical's subsidiary, Yichang Renfu, has been granted a clinical trial approval notice for Pregabalin sustained-release tablets [1] - The drug is aimed at addressing significant medical needs in the treatment of DPN and PHN, indicating potential market opportunities for the company [1]

Core Viewpoint - The announcement highlights that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, indicating a significant step in expanding its treatment applications [1] Company Summary - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu Pharmaceutical, which has recently been granted a clinical trial approval for Pregabalin sustained-release tablets [1] - The initial approval in 2023 was for the treatment of diabetic peripheral neuropathy (DPN) related neuropathic pain, and the new application aims to include postherpetic neuralgia (PHN) as an additional indication [1] Industry Summary - Pregabalin is identified as a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels, thereby reducing the release of neurotransmitters [1] - The clinical applications of Pregabalin primarily target neuropathic pain associated with DPN and PHN, which are significant areas in pain management within the pharmaceutical industry [1]

Core Viewpoint - The announcement highlights that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, indicating a significant step in expanding its treatment applications [1] Group 1: Company Developments - Renfu Pharmaceutical's subsidiary, Yichang Renfu, holds an 80% stake and has recently received a clinical trial approval notice for Pregabalin sustained-release tablets [1] - The initial approval in 2023 was for treating diabetic peripheral neuropathy (DPN) related neuropathic pain, and the new application aims to add postherpetic neuralgia (PHN) as an indication [1] Group 2: Product Information - Pregabalin is a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels, reducing neurotransmitter release [1] - The clinical applications of Pregabalin sustained-release tablets primarily target neuropathic pain associated with DPN and PHN [1]

Core Viewpoint - The company Yichang Renfu, a subsidiary of Renfu Pharmaceutical holding 80% equity, has received approval for clinical trials of the drug Prabirin extended-release tablets for the indication of postherpetic neuralgia [1] Group 1: Clinical Development - Yichang Renfu has been approved to conduct clinical trials for Prabirin extended-release tablets targeting postherpetic neuralgia [1] - This follows the earlier approval in 2023 for the same drug to treat neuropathic pain associated with diabetic peripheral neuropathy [1] - The total investment in this research project has reached approximately 55 million yuan [1] Group 2: Market Potential - The projected national sales for Prabirin formulations in 2024 are estimated to be around 690 million yuan [1] - Following the completion of clinical research, Yichang Renfu plans to apply for production and market launch [1]